MASS News and Press, 908 Devices Inc. From 03/07/23

2023-03-07 14:18:03 ET 908 Devices Inc. (MASS) Q4 2022 Earnings Conference Call March 07, 2023 8:30 AM ET Company Participants Kelly Gura – Investor Relations Kevin Knopp – Chief Executive Officer and Co-Founder Joe Griffith – Chief Financial...

2023-03-07 08:43:52 ET The following slide deck was published by 908 Devices Inc. in conjunction with their 2022 Q4 earnings call. For further details see: 908 Devices Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-07 07:02:25 ET 908 Devices press release ( NASDAQ: MASS ): Q4 GAAP EPS of -$0.31 misses by $0.05 . Revenue of $11.64M (-26.3% Y/Y) beats by $0.21M . 908 Devices expects full year 2023 revenue to be in the range of $48 million to $52 million, representin...

Full Year 2022 revenue increases 11% compared to prior year with desktop revenue increasing 25% 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ...

2023-03-06 12:15:57 ET 908 Devices ( NASDAQ: MASS ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, before market open. The consensus EPS Estimate is -$0.24 (-100.0% Y/Y) and the consensus Revenue Estimate is $11.43M (-27.7% Y/Y). Over the last 3 mo...

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Cowen 43 rd Annual Healthcare Conference in Boston, MA. 908 Devices’ management is scheduled to host a fireside chat...

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2022 before market open on Tuesday, March 7, 2023. Company management will webcast a correspondin...

Summary 908 Devices is a highly rated stock by Wall Street analysts. Seeking Alpha quant ratings state the stock "is at a high risk of performing badly." This article discusses this bull vs. bear tug of war and why the company is a "hold." Investment thesis I have ...

Stephens has initiated 908 Devices ( NASDAQ: MASS ) with an overweight rating saying that company's three main bioprocessing device products will benefit from growth in the cell and gene therapy market and the move toward continuous manufacturing. The firm has $14 price target (~40% u...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...